Ginseng “country of harvest” labeling
This article was originally published in The Tan Sheet
Executive Summary
Ginseng marketers are required to disclose the country where the herbal ingredient was harvested or face a fine under a bill introduced by Sen. Russ Feingold (D-Wisc.) May 20. The "Ginseng Harvest Labeling Act of 2004" (S 2452) is intended to protect Wisconsin farmers, who produce 97% of the country's ginseng, from smugglers who attempt to label their foreign products as "Wisconsin grown," Feingold notes in floor comments. The Senator says his incorporation of suggestions from the Ginseng Board of Wisconsin into the bill make it stronger than legislation he previously introduced on the issue (1"The Tan Sheet" Oct. 23, 2000, In Brief)...
You may also be interested in...
Ginseng labeling
"Country of origin" statement on all products containing the herbal would be required under bill recently introduced by Sen. Feingold (D-Wisc.). Noting the Badger State produces 97% of the ginseng grown in the U.S., Feingold says in his floor comments that smugglers have been switching higher-quality, "lower pesticide and chemical content" product from Wisconsin with cheaper imports. "Chinese ginseng has a retail value of about $5-$6 per pound, while Wisconsin ginseng is valued at roughly $16-$20 per pound," he notes. The bill, S 3005, referred to the Commerce Committee and likely to be taken up next session, stipulates retailers must indicate where their ginseng is grown or face a fine
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.